Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinzaparin in advanced renal cell carcinoma
NCT00293501Phase 2Unknown
- Sponsor
- The University of Vermont
- Start
- Dec 2005
- Primary completion
- Feb 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tinzaparin in renal cell carcinoma (RCC), sponsored by The University of Vermont. Primary endpoint: Plasma prothrombin F1.2, thrombin-antithrombin complexes, and D-dimers at 6 months. Status: unknown.
02
Drugs
tinzaparin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00293501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293501.